Barry J Goldstein

List of Publications by Year
in descending order

75 papers	13,246 citations	50276 46 h-index	85541 71 g-index
151 all docs	151 docs citations	151 times ranked	14377 citing authors

#	Article	IF	Citations
1	A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Journal of Diabetes, 2016, 8, 701-711.	1.8	23
2	Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort. PLoS ONE, 2015, 10, e0136853.	2.5	1
3	Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. Drugs and Aging, 2014, 31, 203-214.	2.7	33
4	Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy, 2013, 4, 119-145.	2.5	109
5	Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology, 2013, 12, 3.	6.8	84
6	Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin. Endocrine Practice, 2013, 19, 751-757.	2.1	7
7	Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placeboâ€controlled 54â€week trial in patients with type 2 diabetes (ä¸€é¡¹ä¸ºæœŸ54å‘¨çš„å¯¹æŒç»»ä½¿ç”¨äºŒç”²åŒè Diabetes, 2013, 5, 68-79.	1.8	39
8	The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*^{â€}. Journal of Diabetes, 2012, 4, 227-237.	1.8	56
9	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders, 2010, 10, 7.	2.2	234
10	AMP-Activated Protein Kinase Deficiency Enhances Myocardial Ischemia/Reperfusion Injury but Has Minimal Effect on the Antioxidant/Antinitrative Protection of Adiponectin. Circulation, 2009, 119, 835-844.	1.6	128
11	Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion, 2009, 25, 569-583.	1.9	122
12	Protective vascular and myocardial effects of adiponectin. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 27-35.	3.3	240
13	Inflammatory Signaling: Another Drug Target to Improve Glycemic Control in Type 2 Diabetes. Clinical and Translational Science, 2008, 1, 43-44.	3.1	0
14	Rottlerin activates AMPK possibly through LKB1 in vascular cells and tissues. Biochemical and Biophysical Research Communications, 2008, 376, 434-438.	2.1	7
15	Type 2 diabetes: pathogenesis and treatment. Lancet, The, 2008, 371, 2153-2156.	13.7	103
16	Adiponectin Protects Against Angiotensin II or Tumor Necrosis Factor Î±â€“Induced Endothelial Cell Monolayer Hyperpermeability. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 899-905.	2.4	58
17	Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovascular Research, 2008, 78, 376-384.	3.8	86
18	Adiponectin regulates albuminuria and podocyte function in mice. Journal of Clinical Investigation, 2008, 118, 1645-56.	8.2	493

#	Article	IF	Citations
19	Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress. Circulation, 2007, 115, 1408-1416.	1.6	411
20	Clinical Translation of â€œA Diabetes Outcome Progression Trialâ€•ADOPTAppropriate Combination Oral Therapies in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1226-1228.	3.6	17
21	Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1703-E1708.	3.5	153
22	Important Role of Nox4 Type NADPH Oxidase in Angiogenic Responses in Human Microvascular Endothelial Cells In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2319-2324.	2.4	164
23	Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care, 2007, 30, 1979-1987.	8.6	453
24	Comment on: Hattori et al. (2007) Globular Adiponectin Activates Nuclear Factor-ÂB and Activating Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts: Diabetes 56:804-808. Diabetes, 2007, 56, e7-e8.	0.6	3
25	Adiponectin suppresses IÎºB kinase activation induced by tumor necrosis factor-Î± or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1836-E1844.	3.5	70
26	Dual PPAR Î±/Î³ Agonists: Promises and Pitfalls in Type 2 Diabetes. American Journal of Therapeutics, 2007, 14, 49-62.	0.9	28
27	Pathogenesis of Type 2 Diabetes. Endocrine Research, 2007, 32, 19-37.	1.2	53
28	Adipokines and vascular disease in diabetes. Current Diabetes Reports, 2007, 7, 25-33.	4.2	49
29	Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. Journal of Clinical Investigation, 2007, 117, 1718-1726.	8.2	228
30	Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Current Medical Research and Opinion, 2006, 22, 1715-1723.	1.9	18
31	TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 347, 1113-1120.	2.1	48
32	AMPK and cell proliferation â€“ AMPK as a therapeutic target for atherosclerosis and cancer. Journal of Physiology, 2006, 574, 63-71.	2.9	457
33	Effect of tesaglitazar, a dual PPARÎ±/Î³ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12â€week dose-ranging trial. Current Medical Research and Opinion, 2006, 22, 2575-2590.	1.9	70
34	Adiponectin Suppression of High-Glucose-Induced Reactive Oxygen Species in Vascular Endothelial Cells: Evidence for Involvement of a cAMP Signaling Pathway. Diabetes, 2006, 55, 1840-1846.	0.6	236
35	Reactive oxygen species production via NADPH oxidase mediates TGF-Î²-induced cytoskeletal alterations in endothelial cells. American Journal of Physiology - Renal Physiology, 2005, 289, F816-F825.	2.7	153
36	Intensive insulin therapy regimens: is there a difference in patient satisfaction?. Nature Clinical Practice Endocrinology and Metabolism, 2005, 1, 80-81.	2.8	0

#	Article	IF	Citations
37	Type 2 diabetes: principles of pathogenesis and therapy. Lancet, The, 2005, 365, 1333-1346.	13.7	1,976
38	Role of Insulin-Induced Reactive Oxygen Species in the Insulin Signaling Pathway. Antioxidants and Redox Signaling, 2005, 7, 1021-1031.	5.4	209
39	Redox Paradox. Diabetes, 2005, 54, 311-321.	0.6	303
40	Hyperglycemia Potentiates H2O2 Production in Adipocytes and Enhances Insulin Signal Transduction: Potential Role for Oxidative Inhibition of Thiol-Sensitive Protein-Tyrosine Phosphatases. Antioxidants and Redox Signaling, 2005, 7, 526-537.	5.4	40
41	The NAD(P)H Oxidase Homolog Nox4 Modulates Insulin-Stimulated Generation of H 2 O 2 and Plays an Integral Role in Insulin Signal Transduction. Molecular and Cellular Biology, 2004, 24, 1844-1854.	2.3	471
42	Integration of multiple downstream signals determines the net effect of insulin on MAP kinase vs. PI 3â€²-kinase activation: potential role of insulin-stimulated H2O2. Cellular Signalling, 2004, 16, 323-331.	3.6	36
43	Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2563-2568.	3.6	584
44	Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochemical and Biophysical Research Communications, 2004, 315, 264-271.	2.1	288
45	Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition. Metabolism: Clinical and Experimental, 2003, 52, 705-712.	3.4	26
46	Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clinical Therapeutics, 2003, 25, 890-903.	2.5	52
47	Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?. Current Medical Research and Opinion, 2003, 19, 192-199.	1.9	10
48	Involvement of AMP-Activated Protein Kinase in Glucose Uptake Stimulated by the Globular Domain of Adiponectin in Primary Rat Adipocytes. Diabetes, 2003, 52, 1355-1363.	0.6	416
49	Insulin resistance: from benign to type 2 diabetes mellitus. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 6, S3-10.	1.4	14
50	Protein-Tyrosine Phosphatases: Emerging Targets for Therapeutic Intervention in Type 2 Diabetes and Related States of Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2474-2480.	3.6	71
51	Insulin resistance as the core defect in type 2 diabetes mellitus. American Journal of Cardiology, 2002, 90, 3-10.	1.6	304
52	Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes/Metabolism Research and Reviews, 2002, 18, S16-S22.	4.0	33
53	Enhancement of post-receptor insulin signaling by trivalent chromium in hepatoma cells is associated with differential inhibition of specific protein-tyrosine phosphatases. Journal of Trace Elements in Experimental Medicine, 2001, 14, 393-404.	0.8	28
54	Hydrogen Peroxide Generated during Cellular Insulin Stimulation Is Integral to Activation of the Distal Insulin Signaling Cascade in 3T3-L1 Adipocytes. Journal of Biological Chemistry, 2001, 276, 48662-48669.	3.4	262

#	Article	IF	Citations
55	Insulin-stimulated Hydrogen Peroxide Reversibly Inhibits Protein-tyrosine Phosphatase 1B in Vivo and Enhances the Early Insulin Action Cascade. Journal of Biological Chemistry, 2001, 276, 21938-21942.	3.4	444
56	Use of an anaerobic environment to preserve the endogenous activity of proteinâ€tyrosine phosphatases isolated from intact cells. FASEB Journal, 2001, 15, 1637-1639.	0.5	20
57	Depot-Specific Variation in Protein-Tyrosine Phosphatase Activities in Human Omental and Subcutaneous Adipose Tissue: A Potential Contribution to Differential Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5973-5980.	3.6	21
58	Tyrosine Dephosphorylation and Deactivation of Insulin Receptor Substrate-1 by Protein-tyrosine Phosphatase 1B. Journal of Biological Chemistry, 2000, 275, 4283-4289.	3.4	357
59	Increased activity and expression of MAP kinase in HCC model rats induced by 3â€²-methyl-4-dimethylamino-azobenzene. Journal of Hepatology, 1999, 31, 725-733.	3.7	19
60	Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Molecular and Cellular Biochemistry, 1998, 182, 91-99.	3.1	159
61	Regulation of Insulin Action by Protein Tyrosine Phosphatases. Vitamins and Hormones, 1998, 54, 67-96.	1.7	31
62	Functional Association between the Insulin Receptor and the Transmembrane Protein-tyrosine Phosphatase LAR in Intact Cells. Journal of Biological Chemistry, 1997, 272, 448-457.	3.4	91
63	Effect of tumor necrosis factor-Î± on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. Journal of Cellular Biochemistry, 1997, 64, 117-127.	2.6	42
64	Cell density-dependent changes in the insulin action pathway: Evidence for involvement of protein-tyrosine phosphatases. , 1996, 61, 31-38.		6
65	The Transmembrane Protein-tyrosine Phosphatase LAR Modulates Signaling by Multiple Receptor Tyrosine Kinases. Journal of Biological Chemistry, 1996, 271, 748-754.	3.4	113
66	Insulin Receptor Signaling Is Augmented by Antisense Inhibition of the Protein Tyrosine Phosphatase LAR. Journal of Biological Chemistry, 1995, 270, 2435-2438.	3.4	143
67	Osmotic Loading of Neutralizing Antibodies Demonstrates a Role for Protein-tyrosine Phosphatase 1B in Negative Regulation of the Insulin Action Pathway. Journal of Biological Chemistry, 1995, 270, 20503-20508.	3.4	211
68	Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism: Clinical and Experimental, 1995, 44, 1175-1184.	3.4	116
69	Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines. Journal of Cellular Physiology, 1993, 154, 486-495.	4.1	15
70	The Insulin Receptor and Its Substrate: Molecular Determinants of Early Events in Insulin Action. , 1993, 48, 291-339.		86
71	Approaches to the molecular cloning of protein-tyrosine phosphatases in insulin-sensitive tissues. Molecular and Cellular Biochemistry, 1992, 109, 107-13.	3.1	10
72	Protein-Tyrosine phosphatases and the regulation of insulin action. Journal of Cellular Biochemistry, 1992, 48, 33-42.	2.6	92

#	Article	IF	Citations
73	Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature, 1991, 352, 73-77.	27.8	1,516
74	Insulin Receptor Messenger Ribonucleic Acid Sequence Alterations Detected by Ribonuclease Cleavage in Patients with Syndromes of Insulin Resistance*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 15-24.	3.6	16
75	Variation in Insulin Receptor Messenger Ribonucleic Acid Expression in Human and Rodent Tissues. Molecular Endocrinology, 1987, 1, 759-766.	3.7	55